US6103260A - Simethicone/anhydrous calcium phosphate compositions - Google Patents

Simethicone/anhydrous calcium phosphate compositions Download PDF

Info

Publication number
US6103260A
US6103260A US08896189 US89618997A US6103260A US 6103260 A US6103260 A US 6103260A US 08896189 US08896189 US 08896189 US 89618997 A US89618997 A US 89618997A US 6103260 A US6103260 A US 6103260A
Authority
US
Grant status
Grant
Patent type
Prior art keywords
simethicone
granular
calcium
phosphate
anhydrous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US08896189
Inventor
Joseph R. Luber
Glenn Madison
Gerard McNally
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johnson and Johnson Consumer Inc
Original Assignee
Johnson and Johnson Consumer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Grant date

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/74Synthetic polymeric materials
    • A61K31/80Polymers containing hetero atoms not provided for in groups A61K31/755 - A61K31/795
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/42Phosphorus; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2009Inorganic compounds
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S514/00Drug, bio-affecting and body treating compositions
    • Y10S514/951Powders, granules or particles of specified mesh or particle size

Abstract

The invention relates to antifoam oral solid dosage form preparations formed from a free flowing granular composition comprising an admixture of simethicone and either one or both of granular anhydrous tribasic calcium phosphate or dibasic calcium phosphate wherein the admixture is a uniform granular composition of not more than 1000 micron particle size which is suitable for compression into a solid dosage form for oral administration.

Description

BACKGROUND OF THE INVENTION

1. Field of the Invention

The present invention relates to antigas/antiflatulent oral solid pharmaceutical dosage forms comprising an admixture of simethicone and anhydrous tribasic or dibasic calcium phosphate, free flowing granular compositions for preparing such dosage forms and methods for their production.

2. Background

Simethicone is a mixture of fully methylated linear siloxane polymers containing repeating units of polydimethylsiloxane stabilized with trimethylsiloxy end-blocking units, and silicon dioxide. Simethicone contains 90.5-99% of polydimethylsiloxane and 4-7% silicon dioxide. The polydimethylsiloxanes present in simethicone are practically inert polymers having a molecular weight of 14,000-21,000. The mixture is a gray, translucent, viscous fluid which is insoluble in water.

When administered orally, simethicone is used as an adjunct in the symptomatic treatment of flatulence, functional gastric bloating, and postoperative gas pains. The clinical use of simethicone is based on its antifoam properties. Silicone antifoams spread on the surface of aqueous liquids, forming a film of low surface tension and thus causing the collapse of foam bubbles. Thus for self medication in over-the-counter preparations, simethicone is used as an antiflatulent to relieve symptoms commonly referred to as gas, including upper GI bloating, pressure, fullness, or stuffed feeling. It is often combined with other gastrointestinal medications, such as antacids, antispasmodics or digestive enzymes and various simethicone formulations are disclosed in the prior art.

Simethicone can be administered orally as a liquid preparation or as solid form for example capsules, chewable or swallowable tablets. The preferred form for ease of administration is a swallowable tablet. The advantage of tablets over liquids is the ease of portability. The advantages of swallowable tablets over chewable tablets include the ease of ingestion and lack of taste. Film coated or gelatin coated tablets are preferred for swallowable tablets.

Historically, in preparing solid simethicone dosage forms, difficulties have been encountered when attempting to incorporate substantial quantities of the liquid simethicone in the solid final blend for tableting. The difficulty has been to achieve sufficient cohesion in the compact for compression, particularly for direct compression tableting, so that the tablet will withstand the rigors of further processing, i.e. film coating, gelatin dipping, printing, packaging and the like. Likewise, difficulties have been encountered in assuring that the viscous liquid simethicone is uniformly distributed throughout the solid formulation and expeditiously dispersed upon administration.

An object of the present invention, therefore, is to provide a composition and process wherein substantial quantities of liquid simethicone can be incorporated into solid tablet formulations for manufacture by a dry blend/direct compression process.

U.S. Pat. No. 4,906,478 discloses a simethicone preparation comprising a powdered combinate of particulate calcium silicate and simethicone. U.S. Pat. No. 5,073,384 discloses simethicone preparations comprising combinates of water soluble agglomerated maltodextrin and simethicone. U.S. Pat. No. 5,458,886 discloses a free-flowing granular composition comprising titanium dioxide having specific particle size and surface area in combination with simethicone. While these methods are of some benefit in achieving a simethicone composition suitable for the dry blend/direct compression manufacturing process, the present invention provides further improvements to accomplish the object of providing a composition which may be easily and inexpensively formulated into potent swallowable or chewable tablets.

SUMMARY OF THE INVENTION

The invention relates to antifoam oral solid dosage form preparations formed from a free flowing granular composition comprising an admixture of simethicone and either one or both of granular anhydrous tribasic calcium phosphate or dibasic calcium phosphate wherein the admixture is a uniform granular composition of not more than 1000 micron particle size which is suitable for compression into a solid dosage form for oral administration. The granular anhydrous tribasic or dibasic calcium phosphate comprises about 30-90% w/w of the admixture combinate. The simethicone comprises about 10-70% w/w of the admixture combinate. In a preferred embodiment, the combinate further comprises 0.5 to 4% w/w of a silicone dioxide or 1.0-30.0% w/w of anhydrous calcium phosphate powder. The free flowing granular composition is admixed with conventional tablet binders and excipients and is compressed into the solid oral dosage forms. Preferably, the simethicone comprises greater than about 8% and less than about 20% w/w of the final blend for compression.

In another aspect of the invention, a process for producing a free flowing granular composition of a simethicone antifoam agent for compression into solid oral dosage forms is provided which comprises forming an admixture of granular anhydrous tribasic or dibasic calcium phosphate, the simethicone antifoam agent and optionally a silicon dioxide or anhydrous calcium phosphate powder by adding the simethicone to the granular tribasic or dibasic calcium phosphate and the optional silicon dioxide or anhydrous calcium phosphate powder, dry blending until uniform and shearing to assure a uniform powder. In a further aspect of the process, the granular composition is then combined with excipient materials or other active ingredients and compressed to provide the solid oral dosage form, preferably in the form of a compressed tablet, which may be further processed by coating with an aqueous film coating or enteric coating and/or gelatin dipped and printed.

Benefits of the anhydrous calcium phosphates/simethicone combinate of the present invention over the aforementioned prior art compositions are that it is both a more free flowing and more stable admixture than one comprising agglomerated maltodextrin/simethicone and it is not prone to separation of the simethicone from the substrate. A benefit over the composition of U.S. Pat. No. 4,906,478 is that the anhydrous calcium phosphate/simethicone combinates have significantly better defoaming activity as measured by U.S. Pharmacopia standards (USP 23, page 1411(Simethicone Tablets monograph).

DETAILED DESCRIPTION

As indicated, the dosage forms of the present invention contain an antifoam agent such as simethicone as an active ingredient. The simethicone preferably conforms to the United States Pharmacopoeia (USP XXII) definition, that is, a mixture of fully methylated linear siloxane polymers containing repeating units of the formula (--(CH3)2 SiO--)n, stabilized with trimethyl siloxy end-blocking units of the formula (--(CH3)3 --SiO--) and silicon dioxide. Other organopolysiloxane antifoam agents are known in the art and may also be used as the active ingredient in this invention. Such organopolylosiloxane antifoam agents are disclosed, for example, in U.S. Pat. No. 5,458,886, and the references discussed therein, hereby incorporated by reference. Typically, the antifoam agents are viscous liquid or paste-like materials. At standard temperature and pressure, simethicone is described as a water-white to gray, translucent, viscous oil-like liquid with a density of 0.965-0.970 grams per cubic centimeter and is immiscible with water and alcohol. Thus, the present invention provides a method for forming free flowing granular compositions from such viscous oily liquid or paste-like antifoam agents, which granular compositions are suitable for compression into solid oral dosage forms.

The amount of simethicone or other organopolysiloxane antifoam agent contained in the solid oral dosage form should be sufficient to provide a therapeutic dosage to a patient suffering from gas or flatulence and associated symptoms. The preferred dosage range for simethicone is in the range of about 20 mg to about 125 mg per dosage unit, generally not to exceed 500 mg/day. The dosage ranges may vary for age and weight of a patient as well as the severity of symptoms.

The tribasic or dibasic calcium phosphate is essentially in the anhydrous form. Commercial forms of anhydrous tribasic or dibasic calcium phosphates are available from Rhone-Poulenc; Mendell and FMC Corp.

In accordance with the present invention, the simethicone is admixed with the granulated anhydrous tribasic or dibasic calcium phosphate to form a uniform free flowing granular composition. Generally, it is desired that the admixture contain a proportionate amount of the simethicone antifoam agent and granular anhydrous calcium phosphate which is consistent with forming a free-flowing granular composition. Preferably, the proportionate amounts of the ingredients of the granular admixture composition is about 10-70% w/w simethicone and about 30-90% w/w granular anhydrous tribasic or dibasic calcium phosphate. The ingredients are blended, sheared and screened to assure a free flowing granular composition of not more than about 1000 micron particle size. Optionally, the granular composition may also contain an amount of a silicone dioxide or anhydrous calcium phosphate powder, preferably Silicon Dioxide NF in an amount of about 0.5-4% w/w or anhydrous calcium phosphate powder in an amount of about 1.0-30.0% w/w of the granular composition.

The simethicone/granular anhydrous calcium phosphate admixture composition is conveniently prepared by a dry blend procedure. The anhydrous tribasic or dibasic calcium phosphate is first granulated either by dry compaction or by wet granulation/drying, preferably by dry compaction. Next, the simethicone compound is added to a moving bed of granular anhydrous tribasic or dibasic calcium phosphate so that the simethicone is uniformly distributed and the granular anhydrous calcium phosphate particle size remains essentially unchanged. The bed is kept in motion by low shear mixers. After the granular anhydrous tribasic or dibasic calcium phosphate bed has absorbed the simethicone and a finely divided granular composition is maintained, the silicon dioxide or anhydrous calcium phosphate powder may be added. The granulation may then be screened through a No. 20 US Standard screen (about 840 microns).

The solid oral dosage forms of the present invention may be prepared in the form of tablets, caplets, gelcaps, capsules, chewable tablets, lozenges, fast dissolving wafers, and other known and effective delivery modes. The free flowing granular simethicone/anhydrous tribasic or dibasic calcium phosphate composition may be admixed with a variety of pharmaceutically acceptable excipients including fillers, binders, sweeteners, artificial sweeteners, lubricants, glidants, disintegrants, colors, adsorbents, acidifying agents, and flavoring agents. The choice of excipient will depend on the solid oral dosage form employed (i.e. tablets, caplets, or capsules) and whether the dosage form is chewable or a swallowable formulation. Swallowable oral tablets prepared by direct compression are preferred. Excipients which are compatible with direct compression tablet formulations are preferred. For example, excipients chosen from the following list may be employed:

a) diluents such as lactose, kaolin, mannitol, crystalline sorbitol, additional dibasic or calcium phosphates and the like;

b) binders such as sugars, microcrystalline cellulose, carboxymethyl cellulose, hydroxyethyl cellulose, polyvinylpyrrolidone and the like;

c) lubricants such as magnesium stearate, talc, calcium stearate, zinc stearate, stearic acid, hydrogenated vegetable oil, leucine, glycerides and sodium stearyl fumarate;

d) disintegrants such as starches, croscarmellose sodium, methylcellulose, agar, bentonite, alginic acid, carboxymethylcellulose, polyvinylpyrrolidone and the like;

e) scavengers such as charcoal, silicon dioxide, anhydrous calcium phosphates;

f) flavoring agents such as mannitol, dextrose, fructose, sorbitol and the like; and

g) coloring agents.

Other suitable excipients can be found in the Handbook of Pharmaceutical Excipients, published by the American Pharmaceutical Association, herein incorporated by reference.

A typical dosage form of the present invention may have a formulation containing various components in accordance with the following:

______________________________________Free flowing Simethicone Admixture                    10% to 99%Tribasic Calcium Phosphate, Anhydrous                          45% to 80%Simethicone USP                                      10% to 50%Scavenger e.g. Silicon Dioxide, NF                              1% to 10%or Anhydrous Calcium Phosphate PowderExcipients                                                 1% to 90%Diluent                                                       0% to 40%Binders                                                       0% to 10%Lubricant                                                  0% to 1.5%Scavenger                                                   0% to 10%Flavorant/Colorants                               0% to______________________________________                    5%

Preferably, the simethicone content of the final tablet formulation comprises about 8% to about 20% w/w of the final blend. The production of the oral dosage forms of the invention are carried out by methods known in the art, for example, by granulating the anhydrous tribasic or dibasic calcium phosphate using either dry compaction or wet granulation techniques; forming the free flowing simethicone/granular anhydrous tribasic or dibasic calcium phosphate admixture; mixing the free flowing simethicone/granular anhydrous tribasic or dibasic calcium phosphate composition with the excipients and then forming the composition into the dosage form by methods known in the art, for example by direct compression, dry granulation or the like. Suitable manufacturing methods for oral solid dosage forms are disclosed in Remington's Pharmaceutical Science, 18th Edition, published by Mack Publishing Company, hereby incorporated by reference. Preferably, the manufacturing procedure generally involves preparing the free flowing simethicone/granular anhydrous tribasic or dibasic calcium phosphate admixture as described above, adding the additional binder/diluent/disintegrant excipients with low shear blending, adding a lubricant and preparing tablets by direct compression.

Optionally, the dosage form can include one or more additional active ingredients suitable for the treatment of gastrointestinal disorders, for example heartburn, ulcers or diarrhea. Suitable active agents for treating gastrointestinal disorders include heartburn or antiulcer medicaments such as sucralfate, the H2 receptor antagonists cimetidine, ranitidine, famotidine or nizatidine, proton pump inhibitors such as omeprazole or lansoprazole; antidiarrheal agents such as loperamide and diphenoxylate; gastrointestinal motility agents such as cisapride, and antacids such as aluminum hydroxide, magnesium carbonate, magnesium hydroxide, calcium carbonate and the like. The amount of such additional active ingredient combined with the simethicone should be an amount sufficient to provide a therapeutic dosage to a patient suffering from the gastrointestinal disorder being treated.

The following examples are provided to further illustrate the present invention:

EXAMPLE 1 Preparation of Simethicone/Granular Anhydrous Tribasic Calcium Phosphate Admixture

1.700 gm of granular tricalcium phosphate (Tritab®, Rhone-Poulenc, Shelton, Conn.) is added to the mixing bowl of a Kitchen Aid mixer.

2. While mixing at low speed, over a period of 5 minutes add 200 gm of simethicone, USP.

3. Continue mixing at low speed for an additional 5 minutes.

4. Add 2.5 gm of silicon dioxide and mix an additional 5 minutes.

This intermediate is a free flowing granulation with no large agglomerates.

EXAMPLE 2 Preparation of Simethicone/Granular Anhydrous Dibasic Calcium Phosphate Admixture

1) 700 gm of granular anhydrous dibasic calcium phosphate, (Emcompress® Anhydrous, Mendell, Paterson, N.J.) is added to the mixing bowl of a Kitchen Aid mixer.

2) While mixing a low speed, over a period of 5 minutes add 200 gm of simethicone, USP.

3) Continue mixing at low speed for an additional 5 minutes.

4) Add 7.5 gm of silicon dioxide and mix an additional 5 minutes.

This intermediate is a free flowing granulation with no large agglomerates.

COMPARATIVE EXAMPLE 2 Preparation of Simethicone/Granular Dibasic Calcium Phosphate Dihydrate Admixture

1) 700 gm of granular Dicalcium phosphate, Dihydrate (Emcompress®, Mendell, Paterson, N.J.) is added to the mixing bowl of a Kitchen Aid mixer.

2) While mixing at low speed, over a period of 5 minutes add 200 gm of simethicone, USP.

3) Continue mixing at low speed for an additional 5 minutes.

4) Add 30 gm of silicon dioxide and mix an additional 5 minutes.

This intermediate is NOT a free flowing granulation. It contains many large agglomerates.

EXAMPLE 3 Preparation of Chewable Tablets Containing Simethicone/Granular Anhydrous Tribasic Calcium Phosphate Admixture

1) 89 gm of the free flowing granular intermediate from Example 1 was then blended with 98 gm of Dextrates, 7.5 gm granular sorbitol, 0.6 gm peppermint flavor, and 0.5 gm stearic acid.

2) The blend was finally compressed using 5/8" FFBE tooling. The tablet weight was 1300 mg. The physical properties of the tablet were:

Hardness: 8-10 kp

Friability: less than 0.1% at 100 drops

Disintegration in water: less than 1 minute

Defoam: 5 secs.

EXAMPLE 4 Preparation of Chewable Tablets Containing Simethicone/Granular Anhydrous Tribasic Calcium Phosphate Admixture

1) 1500 gm of tricalcium phosphate powder was dry granulated by roller compacting at a roll pressure of 500 psi.

2) The compact was passed through a Fitz Mill with a 0.093" screen, knives forward.

3) The milled material was screened, and the -30 to +80 mesh fraction collected as product.

4) 700 gm of compacted tricalcium phosphate granules was added to the mixing bowl of a Kitchen Aid mixer.

5) While mixing a low speed, over a period of 5 minutes add 200 gm of simethicone, USP.

6) Continue mixing at low speed for an additional 5 minutes.

7) Add 20 gm of tricalcium phosphate powder and mix an additional 5 minutes.

This intermediate is a free flowing granulation with no large agglomerates.

8) 91 gm of the above intermediate was then blended with 98 gm of Dextrates, 7.5 gm granular sorbitol, 0.6 gm peppermint flavor, and 0.5 gm stearic acid.

9) The blend was finally compressed using 5/8" FFBE tooling. The tablet weight was 1300 mg. The physical properties of the tablet were:

Hardness: 11-12 kp

Friability: less than 0.1% at 100 drops

Disintegration in N/10 HCl: less than 1.5 minute

Defoam: 7 secs

EXAMPLE 5 Preparation of Chewable Tablets Containing Simethicone/Granular Anhydrous Tribasic Calcium Phosphate Admixture

1) 500 gm of tricalcium phosphate powder and 50 gm of pregel starch were dry blended in a Kitchen Aid mixer.

2) 310 gm of purified water was slowly added to the mixer with continuous mixing.

3) The wet granulation was passed through a #12 mesh screen and then dried for 5 hours at 50° C.

4) The dried granules were passed through a #18 mesh screen and material less than #70 mesh was removed.

5) Steps 1-4 were repeated.

6) Then 700 gm of granulated tricalcium phosphate/pregel starch granules is added to the mixing bowl of a Kitchen Aid mixer.

7) While mixing a low speed, over a period of 5 minutes add 200 gm of simethicone, USP.

8) Continue mixing at low speed for an additional 5 minutes.

This intermediate is a free flowing granulation with no large agglomerates.

9) 89 gm of the above intermediate was then blended with 98 gm of Dextrates, 7.5 gm granular sorbitol, 0.6 gm peppermint flavor, and 0.5 gm stearic acid.

10)The blend was finally compressed using 5/8" FFBE tooling. The tablet weight was 1300 mg, and its physical properties were:

Hardness: 8-9 kp

Friability: less than 0.1% at 100 drops

Disintegration in N/10 HCl: less than 1 minute

Defoam: 5 secs.

EXAMPLE 6 Preparation of Swallowable Film Coated Tablets Containing Simethicone/Granular Anhydrous Tribasic Calcium Phosphate Admixture

______________________________________Ingredient              Qty mg/tab______________________________________PART I - concentrateTribasic calcium phosphate, NF,                         500Anhydrous, granularSimethicone, USP                             125Tribasic calcium phosphate, NF,                         25Anhydrous, PowderPART II- ScavengerTribasic calcium phosphate, NF,                         20Anhydrous, PowderPART III- Excipient/Binder systemDibasic calcium phosphate, Dihydrate,                   105.75USPMicrocrystalline cellulose, NF (MCC)                     53Crystalline sorbitol, NF                                70Croscarmellose sodium, NF                               30PART IV-LubricantMagnesium Stearate, NF                0.5______________________________________

PART 1) A concentrate comprised of granular and powdered anhydrous tribasic calcium phosphates, and simethicone is prepared by adding simethicone compound, USP to a moving bed of granular tribasic calcium phosphate so that the simethicone is distributed evenly and the granular calcium phosphate particle size remains essentially unchanged. The bed is kept in motion by low shear mixers such as fluid bed, Nauta, PK without intensifier bar, pin mixer, or ribbon mixer. After the bed has adsorbed the simethicone, anhydrous tribasic calcium phosphate powder is added. The granulation may then be screened through a No. 20 US Std screen (˜840 micron).

PART 2) When a final blend for compression is desired an additional quantity of calcium phosphate powder is added to the PART 1 concentrate and blended.

PART 3) Excipients including a disintegrant are then added with low shear blending which imparts uniform distribution of the active within a binding matrix of limited compositional range.

PART 4) The final addition step is to add a lubricant.

PART 5) The blend is compressed into tablets using a rotary tablet press.

PART 6) Tablets are then film coated and/for gelatin dipped.

Typical film coated tablet characteristics:

Hardness range: 6-14 kp

Tablet weight (core): Approx. 1000 mg

USP disintegration time in water : Less than 7 minutes, in acid media : Less than 6 minutes

USP Defoaming activity time: 9 seconds

Claims (12)

We claim:
1. An antifoam simethicone free-flowing granular composition suitable for use as an oral solid dosage form preparation formed by (i) preparing a granular composition consisting essentially of an admixture of (a) simethicone and (b) granular anhydrous tribasic or dibasic calcium phosphate or a mixture thereof; wherein the simethicone is adsorbed by the granular anhydrous tribasic or dibasic calcium phosphate or mixture thereof, and wherein the simethicone/calcium phosphate admixture is a uniform granular composition of not more than 1000 micron particle size, and (ii) admixing the uniform granular composition with one or more excipients to form the free-flowing granular composition.
2. An oral solid dosage form of claim 1 wherein said dosage form is in the form of a unit dose compressed swallowable or chewable tablet, or caplet, gelcap, capsule, lozenge or fast dissolving wafer.
3. An oral solid dosage form of claim 1 further containing one or more excipients in addition to said free flowing granular composition.
4. An oral solid dosage form of claim 3 wherein said excipients are selected from one or more fillers, binders, sweeteners, artificial sweeteners, lubricants, glidants, disintegrants, colors, adsorbents, acidifying agents, and flavoring agents.
5. An oral solid dosage form of claim 1 wherein the simethicone content of the dosage form comprises about 8% to about 20% w/w.
6. An oral solid dosage form of claim 5 further containing crystalline sorbitol, microcrystalline cellulose and anhydrous tribasic or dibasic calcium phosphate as excipients in addition to the free flowing granular composition of simethicone and granular anhydrous tribasic or dibasic calcium phosphate.
7. An antifoam simethicone oral solid dosage form preparation formed by (i) preparing a free-flowing granular composition consisting essentially of an admixture of (a) simethicone and (b) granular anhydrous tribasic or dibasic calcium phosphate or a mixture thereof; wherein the simethicone is adsorbed by the granular anhydrous tribasic or dibasic calcium phosphate or mixture thereof to form the free-flowing granular composition, and wherein the simethicone/calcium phosphate admixture is a uniform granular composition of not more than 1000 micron particle size, and (ii) admixing the free-flowing granular composition with one or more excipients and one or more additional active ingredients suitable for the treatment of gastrointestinal disorders, to form the oral solid dosage form preparation.
8. The oral solid dosage form of claim 7 wherein the additional active ingredient is selected from one or more of the following: H2 receptor antagonists, proton pump inhibitors, antidiarrheal agents, gastrointestinal motility agents, and antacids.
9. A free flowing granular composition comprising an admixture of (a) simethicone and (b) granular anhydrous tribasic or dibasic calcium phosphate or a mixture thereof; wherein the simethicone/calcium phosphate admixture is a uniform granular composition of not more than 1000 micron particle size.
10. The free flowing granular composition of claim 9 wherein the proportionate amounts of the ingredients of the granular admixture composition is about 10-70% w/w simethicone and about 30-90% w/w granular anhydrous tribasic or dibasic calcium phosphate.
11. The free flowing granular composition of claim 9 further containing either Silicon Dioxide in an amount of about 0.5-4% w/w or anhydrous calcium phosphate powder in an amount of about 1-30% w/w of the granular composition.
12. A process for producing a free flowing granular composition of a simethicone antifoam agent for compression into solid oral dosage forms which comprises forming an admixture of granular anhydrous tribasic and/or dibasic calcium phosphate, the simethicone antifoam agent and optionally a scavenger by adding the simethicone to the granular anhydrous tribasic or dibasic calcium phosphate and the optional scavenger, dry blending until uniform and shearing to assure a uniform free flowing granular composition.
US08896189 1997-07-17 1997-07-17 Simethicone/anhydrous calcium phosphate compositions Expired - Lifetime US6103260A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US08896189 US6103260A (en) 1997-07-17 1997-07-17 Simethicone/anhydrous calcium phosphate compositions

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US08896189 US6103260A (en) 1997-07-17 1997-07-17 Simethicone/anhydrous calcium phosphate compositions
JP21344698A JPH1192387A (en) 1997-07-17 1998-07-14 Simethicone/calcium phosphate anhydride composition
DE1998621553 DE69821553D1 (en) 1997-07-17 1998-07-16 Granular formulation containing simethicone and granular anhydrous calcium phosphate
EP19980305696 EP0891776B1 (en) 1997-07-17 1998-07-16 Granular composition comprising simethicone and granular anhydrous calcium phosphate
RU98114678A RU2216317C2 (en) 1997-07-17 1998-07-16 Composition simethicone/anhydrous calcium phosphate
DE1998621553 DE69821553T2 (en) 1997-07-17 1998-07-16 Granular formulation containing simethicone and granular anhydrous calcium phosphate
DK98305696T DK0891776T3 (en) 1997-07-17 1998-07-16 A granular composition comprising simethicone and granular anhydrous calcium phosphate
ES98305696T ES2216244T3 (en) 1997-07-17 1998-07-16 based composition granular simethicone and anhydrous calcium phosphate in the form of granulated.
CN 98117598 CN1267106C (en) 1997-07-17 1998-07-17 Simethicone/anhydrous calcium phosphate compositions

Publications (1)

Publication Number Publication Date
US6103260A true US6103260A (en) 2000-08-15

Family

ID=25405781

Family Applications (1)

Application Number Title Priority Date Filing Date
US08896189 Expired - Lifetime US6103260A (en) 1997-07-17 1997-07-17 Simethicone/anhydrous calcium phosphate compositions

Country Status (8)

Country Link
US (1) US6103260A (en)
EP (1) EP0891776B1 (en)
JP (1) JPH1192387A (en)
CN (1) CN1267106C (en)
DE (2) DE69821553T2 (en)
DK (1) DK0891776T3 (en)
ES (1) ES2216244T3 (en)
RU (1) RU2216317C2 (en)

Cited By (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6326384B1 (en) * 1999-08-26 2001-12-04 Robert R. Whittle Dry blend pharmaceutical unit dosage form
US20030091624A1 (en) * 2001-09-28 2003-05-15 Szymczak Christopher E. Simethicone solid oral dosage form
US20030229158A1 (en) * 2001-09-28 2003-12-11 Chen Jen Chi Polymer composition and dosage forms comprising the same
US20030235616A1 (en) * 2001-09-28 2003-12-25 Sowden Harry S. Modified release dosage form
US20040063664A1 (en) * 2002-09-30 2004-04-01 Danielson Douglas W. Simethicone containing tablet composition and method
WO2004028508A1 (en) 2002-09-28 2004-04-08 Mcneil-Ppc, Inc. Modified release dosage forms with two cores and an opening
US6753009B2 (en) 2002-03-13 2004-06-22 Mcneil-Ppc, Inc. Soft tablet containing high molecular weight polyethylene oxide
US20040146559A1 (en) * 2002-09-28 2004-07-29 Sowden Harry S. Dosage forms having an inner core and outer shell with different shapes
US20040156902A1 (en) * 2002-09-28 2004-08-12 Der-Yang Lee Composite dosage forms having an inlaid portion
US20040185093A1 (en) * 2003-03-18 2004-09-23 Szymczak Christopher E. Compositions containing sucralose
US20040265373A1 (en) * 2003-06-27 2004-12-30 David Wynn Soft tablet containing high molecular weight cellulosics
US20050019376A1 (en) * 2001-09-28 2005-01-27 Mcnally Gerard P. Dosage form containing a confectionery composition
US20050069590A1 (en) * 2003-09-30 2005-03-31 Buehler Gail K. Stable suspensions for medicinal dosages
US20050074514A1 (en) * 2003-10-02 2005-04-07 Anderson Oliver B. Zero cycle molding systems, methods and apparatuses for manufacturing dosage forms
US20050095299A1 (en) * 2003-10-30 2005-05-05 Wynn David W. Controlled release analgesic suspensions
US20050095300A1 (en) * 2003-10-30 2005-05-05 Wynn David W. Controlled release analgesic suspensions
US20050152970A1 (en) * 2004-01-13 2005-07-14 Rinker Roger A. Rapidly disintegrating gelatinous coated tablets
US20050152971A1 (en) * 2004-01-13 2005-07-14 Rinker Roger A. Rapidly disintegrating gelatinous coated tablets
US20050196446A1 (en) * 2004-03-05 2005-09-08 Huang Hai Y. Polymeric compositions and dosage forms comprising the same
US20050196447A1 (en) * 2004-03-05 2005-09-08 Huang Hai Y. Polymeric compositions and dosage forms comprising the same
US20050196448A1 (en) * 2004-03-05 2005-09-08 Hai Yong Huang Polymeric compositions and dosage forms comprising the same
US20050196442A1 (en) * 2004-03-05 2005-09-08 Huang Hai Y. Polymeric compositions and dosage forms comprising the same
EP1602363A1 (en) 2004-06-04 2005-12-07 McNeil-PPC, Inc. Immediate release dosage form comprising shell having openings therein
US20060046998A1 (en) * 2004-08-25 2006-03-02 Fairfield Clinical Trials, Llc Method of treatment of gastroesophageal reflux disease and laryngopharyngeal reflux disease
US20060062811A1 (en) * 2004-09-21 2006-03-23 Szymczak Christopher E Medicinal cooling emulsions
US20060088585A1 (en) * 2004-10-27 2006-04-27 Bunick Frank J Dosage forms having a microreliefed surface and methods and apparatus for their production
US20060088587A1 (en) * 2004-10-27 2006-04-27 Bunick Frank J Dosage forms having a microreliefed surface and methods and apparatus for their production
US20060087051A1 (en) * 2004-10-27 2006-04-27 Bunick Frank J Dosage forms having a microreliefed surface and methods and apparatus for their production
US20060088586A1 (en) * 2004-10-27 2006-04-27 Bunick Frank J Dosage forms having a microreliefed surface and methods and apparatus for their production
US20060088593A1 (en) * 2004-10-27 2006-04-27 Bunick Frank J Dosage forms having a microreliefed surface and methods and apparatus for their production
US20060094787A1 (en) * 2003-03-12 2006-05-04 Patrick Forenzo Pharmaceutical composition comprising 5-methyl-2-2'(chloro-6'-fluoroanilino) phenylacetic acid
US20070190133A1 (en) * 2004-10-27 2007-08-16 Bunick Frank J Dosage forms having a microreliefed surface and methods and apparatus for their production
US20070281022A1 (en) * 2004-10-27 2007-12-06 Bunick Frank J Dosage forms having a microreliefed surface and methods and apparatus for their production
US20080069880A1 (en) * 2002-05-15 2008-03-20 Bunick Frank J Enrobed core
US20080103206A1 (en) * 2006-10-20 2008-05-01 Jim Swann Acetaminophen / ibuprofen combinations and method for their use
US20080113021A1 (en) * 2006-10-25 2008-05-15 Robert Shen Ibuprofen composition
US20080311201A1 (en) * 2007-06-12 2008-12-18 Lee Der-Yang Modified release solid or semi-solid dosage forms
US20090004248A1 (en) * 2007-06-29 2009-01-01 Frank Bunick Dual portion dosage lozenge form
US20090060983A1 (en) * 2007-08-30 2009-03-05 Bunick Frank J Method And Composition For Making An Orally Disintegrating Dosage Form
US20090074866A1 (en) * 2007-09-17 2009-03-19 Jen-Chi Chen Dip coated compositions containing copolymer of polyvinyl alcohol and polyethylene glycol and a gum
US20090110716A1 (en) * 2007-10-31 2009-04-30 Frank Bunick Orally disintegrative dosage form
US20090162435A1 (en) * 2007-12-21 2009-06-25 Bunick Frank J Manufacture of tablet
US20090191267A1 (en) * 2005-09-30 2009-07-30 Wynn David W Oral Compositions Containing a Salivation Inducing Agent
US20090196907A1 (en) * 2008-01-31 2009-08-06 Bunick Frank J Edible film-strips for immediate release of active ingredients
US20090196908A1 (en) * 2008-01-31 2009-08-06 Der-Yang Lee Edible film-strips with modified release active ingredients
US20090208574A1 (en) * 2008-02-19 2009-08-20 Jen-Chi Chen Dip coated compositions containing a starch having a high amylose content
US20090258039A1 (en) * 2002-12-04 2009-10-15 Bunick Frank J Method of administering a pharmaceutical active ingredient
US20090324716A1 (en) * 2008-06-26 2009-12-31 Robert Shen Coated Particles Containing Pharmaceutically Active Agents
WO2010006029A2 (en) 2008-07-08 2010-01-14 Hyperbranch Medical Technology, Inc. Self-contained medical applicators for multiple component formulations, and methods of use thereof
US20100092555A1 (en) * 2003-06-27 2010-04-15 David Wynn Soft tablet containing high molecular weight cellulosics
US20100112052A1 (en) * 2008-10-31 2010-05-06 Vincent Chen Osmotic tablet with a compressed outer coating
US20100247586A1 (en) * 2009-03-27 2010-09-30 Andreas Hugerth Multi-Portion Intra-Oral Dosage Form With Organoleptic Properties
US20100249237A1 (en) * 2003-03-21 2010-09-30 Gelotte Cathy K Non-Steroidal Anti-Inflammatory Drug Dosing Regimen
US7838026B2 (en) 2001-09-28 2010-11-23 Mcneil-Ppc, Inc. Burst-release polymer composition and dosage forms comprising the same
US20100330169A1 (en) * 2009-06-29 2010-12-30 Frank Bunick Pharmaceutical Tablet Containing A Liquid Filled Capsule
US20110070286A1 (en) * 2009-09-24 2011-03-24 Andreas Hugerth Process for the manufacture of nicotine-comprising chewing gum and nicotine-comprising chewing gum manufactured according to said process
US20110071183A1 (en) * 2009-09-24 2011-03-24 Jen-Chi Chen Manufacture of lozenge product with radiofrequency
US20110104288A1 (en) * 2009-11-05 2011-05-05 Fmc Corporation Microcrystalline Cellulose and Calcium Phosphate Compositions Useful as Pharmaceutical Excipients
US8114328B2 (en) 2001-09-28 2012-02-14 Mcneil-Ppc, Inc. Method of coating a dosage form comprising a first medicant
WO2012039790A1 (en) 2010-09-22 2012-03-29 Mcneil-Ppc, Inc. Manufacture of tablets from energy-applied powder blend
WO2012039788A1 (en) 2010-09-22 2012-03-29 Mcneil-Ppc, Inc. Multi-layered orally disintegrating tablet and the manufacture thereof
US8313768B2 (en) 2009-09-24 2012-11-20 Mcneil-Ppc, Inc. Manufacture of tablet having immediate release region and sustained release region
US8394415B2 (en) 2006-11-21 2013-03-12 Mcneil-Ppc, Inc Modified release analgesic suspensions
WO2013095111A1 (en) 2011-12-14 2013-06-27 Disphar International B.V. Simethicone formulation
WO2013119466A1 (en) 2012-02-07 2013-08-15 Mcneil-Ppc, Inc. Rapidly disintegrating coated tablets
WO2013166131A2 (en) 2012-05-01 2013-11-07 Mcneil-Ppc, Inc. Orally disintegrating tablet
WO2013166136A1 (en) 2012-05-01 2013-11-07 Mcneil-Ppc, Inc. Tablet comprising a first and second region
WO2013166144A1 (en) 2012-05-01 2013-11-07 Mcneil-Ppc, Inc. Method of manufacturing solid dosage form
WO2013166138A1 (en) 2012-05-01 2013-11-07 Mcneil-Ppc, Inc. Machine for production of solid dosage forms
US8673352B2 (en) 2005-04-15 2014-03-18 Mcneil-Ppc, Inc. Modified release dosage form
US8858210B2 (en) 2009-09-24 2014-10-14 Mcneil-Ppc, Inc. Manufacture of variable density dosage forms utilizing radiofrequency energy
WO2015105992A1 (en) 2014-01-10 2015-07-16 Mcneil-Ppc, Inc. Process for making tablet using radiofrequency and lossy coated particles
WO2018017553A2 (en) 2016-07-19 2018-01-25 Johnson & Johnson Consumer Inc. Tablets having discontinuous coated regions

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6793934B1 (en) * 1999-12-08 2004-09-21 Shire Laboratories, Inc. Solid oral dosage form
US8748489B2 (en) * 2006-08-10 2014-06-10 Procaps SAS Solid pharmaceutical composition containing a combination of an intestinal motility regulating agent and an antiflatulent
US8491937B2 (en) 2007-02-15 2013-07-23 Wyeth Llc Stability in vitamin and mineral supplements
CN103429237A (en) * 2010-11-16 2013-12-04 Posi幻影技术有限公司 Orally administered pharmaceutical composition for the treatment of irritable bowel syndrome, comprising an intestinal motility modifier, an agent that prevents gas retention, and digestive enzymes, and preparation method thereof
GB201315559D0 (en) * 2013-08-02 2013-10-16 Tate & Lyle Ingredients Sweetener compositions
WO2016114734A1 (en) 2015-01-16 2016-07-21 Biofarma Ilaç Sanayi Ve Ticaret A. Ş. Pharmaceutical formulation of trimebutine maleate and simethicone comprising acidifying agent
EP3173076A1 (en) 2015-05-14 2017-05-31 Abdi Ibrahim Ilac Sanayi ve Ticaret A.S. A pharmaceutical composition comprising simethicone and otilonium
EP3294269A1 (en) 2015-06-12 2018-03-21 Santa Farma Ilaç Sanayi A.S. Oral pharmaceutical composition comprising otilonium bromide and simethicone with certain bulk density and improved dissolution characteristics

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB914925A (en) * 1960-10-10 1963-01-09 Plough Therapeutic compositions containing organopolysiloxanes
US4127650A (en) * 1975-03-31 1978-11-28 William H. Rorer, Inc. Medicinal simethicone containing composition and its method of production
US4396604A (en) * 1982-05-17 1983-08-02 Norcliff Thayer, Inc. Simethicone antacid lozenge
US4557916A (en) * 1984-10-22 1985-12-10 J. M. Huber Corporation Synthetic calcium silicates and methods of preparation
EP0263224A2 (en) * 1986-09-09 1988-04-13 Warner-Lambert Company Chewing gum mineral supplement
US4906478A (en) * 1988-12-12 1990-03-06 Valentine Enterprises, Inc. Simethicone/calcium silicate composition
US5073384A (en) * 1989-10-19 1991-12-17 Valentine Enterprises, Inc. Maltodextrin/defoaming composition combinate
EP0465234A1 (en) * 1990-07-03 1992-01-08 McNEIL-PPC, INC. Pharmaceutical compositions and methods for alleviating gastrointestinal distress symptoms induced by nonsteroidal anti-inflammatory drugs
EP0571217A2 (en) * 1992-05-21 1993-11-24 McNEIL-PPC, INC. Novel simethicone containing pharmaceutical compositions for treating gastrointestinal distress
US5275822A (en) * 1989-10-19 1994-01-04 Valentine Enterprises, Inc. Defoaming composition
US5458886A (en) * 1993-06-04 1995-10-17 Dow Corning France S.A. Antifoam compositions

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB914925A (en) * 1960-10-10 1963-01-09 Plough Therapeutic compositions containing organopolysiloxanes
US4127650A (en) * 1975-03-31 1978-11-28 William H. Rorer, Inc. Medicinal simethicone containing composition and its method of production
US4396604A (en) * 1982-05-17 1983-08-02 Norcliff Thayer, Inc. Simethicone antacid lozenge
US4557916A (en) * 1984-10-22 1985-12-10 J. M. Huber Corporation Synthetic calcium silicates and methods of preparation
EP0263224A2 (en) * 1986-09-09 1988-04-13 Warner-Lambert Company Chewing gum mineral supplement
US4906478A (en) * 1988-12-12 1990-03-06 Valentine Enterprises, Inc. Simethicone/calcium silicate composition
US5073384A (en) * 1989-10-19 1991-12-17 Valentine Enterprises, Inc. Maltodextrin/defoaming composition combinate
US5275822A (en) * 1989-10-19 1994-01-04 Valentine Enterprises, Inc. Defoaming composition
EP0465234A1 (en) * 1990-07-03 1992-01-08 McNEIL-PPC, INC. Pharmaceutical compositions and methods for alleviating gastrointestinal distress symptoms induced by nonsteroidal anti-inflammatory drugs
EP0571217A2 (en) * 1992-05-21 1993-11-24 McNEIL-PPC, INC. Novel simethicone containing pharmaceutical compositions for treating gastrointestinal distress
US5599577A (en) * 1992-05-21 1997-02-04 Mcneil-Ppc, Inc. Simethicone containing pharmaceutical compositions
US5458886A (en) * 1993-06-04 1995-10-17 Dow Corning France S.A. Antifoam compositions

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
European Search Report Application No. 98305696 dated Oct. 22, 1998. *

Cited By (145)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6326384B1 (en) * 1999-08-26 2001-12-04 Robert R. Whittle Dry blend pharmaceutical unit dosage form
US7972624B2 (en) 2001-09-28 2011-07-05 Shun-Por Li Method of manufacturing modified release dosage forms
US20030229158A1 (en) * 2001-09-28 2003-12-11 Chen Jen Chi Polymer composition and dosage forms comprising the same
US20030235616A1 (en) * 2001-09-28 2003-12-25 Sowden Harry S. Modified release dosage form
US20040018327A1 (en) * 2001-09-28 2004-01-29 David Wynn Delayed release dosage forms
US20070196468A1 (en) * 2001-09-28 2007-08-23 Szymczak Christopher E Simethicone solid oral dosage form
US20040062804A1 (en) * 2001-09-28 2004-04-01 Der-Yang Lee Modified release dosage forms
US7416738B2 (en) 2001-09-28 2008-08-26 Mcneil-Ppc, Inc. Modified release dosage form
US8673190B2 (en) 2001-09-28 2014-03-18 Mcneil-Ppc, Inc. Method for manufacturing dosage forms
US20030091624A1 (en) * 2001-09-28 2003-05-15 Szymczak Christopher E. Simethicone solid oral dosage form
US8545887B2 (en) 2001-09-28 2013-10-01 Mcneil-Ppc, Inc. Modified release dosage forms
US20040170750A1 (en) * 2001-09-28 2004-09-02 Bunick Frank J. Edible composition and dosage form comprising an edible shell
US7691409B2 (en) 2001-09-28 2010-04-06 Mcneil-Ppc, Inc. Simethicone solid oral dosage form
US20040213848A1 (en) * 2001-09-28 2004-10-28 Shun-Por Li Modified release dosage forms
US20040213849A1 (en) * 2001-09-28 2004-10-28 Sowden Harry S. Modified release dosage forms
US20040241236A1 (en) * 2001-09-28 2004-12-02 Shun-Por Li Modified release dosage forms
US20040241208A1 (en) * 2001-09-28 2004-12-02 Sowden Harry S. Fondant-based pharmaceutical composition
US7838026B2 (en) 2001-09-28 2010-11-23 Mcneil-Ppc, Inc. Burst-release polymer composition and dosage forms comprising the same
US20090186082A1 (en) * 2001-09-28 2009-07-23 Shun-Por Li Method of manufacturing modified release dosage forms
US8114328B2 (en) 2001-09-28 2012-02-14 Mcneil-Ppc, Inc. Method of coating a dosage form comprising a first medicant
US20050019376A1 (en) * 2001-09-28 2005-01-27 Mcnally Gerard P. Dosage form containing a confectionery composition
US7968120B2 (en) 2001-09-28 2011-06-28 Mcneil-Ppc, Inc. Modified release dosage forms
US20100135982A1 (en) * 2001-09-28 2010-06-03 Szymczak Christopher E Simethicone solid oral dosage form
US7101573B2 (en) * 2001-09-28 2006-09-05 Mcneil-Pcc, Inc. Simethicone solid oral dosage form
US6753009B2 (en) 2002-03-13 2004-06-22 Mcneil-Ppc, Inc. Soft tablet containing high molecular weight polyethylene oxide
US7955652B2 (en) 2002-05-15 2011-06-07 Mcneil-Ppc, Inc. Enrobed core
US20080069880A1 (en) * 2002-05-15 2008-03-20 Bunick Frank J Enrobed core
US20040156902A1 (en) * 2002-09-28 2004-08-12 Der-Yang Lee Composite dosage forms having an inlaid portion
WO2004028508A1 (en) 2002-09-28 2004-04-08 Mcneil-Ppc, Inc. Modified release dosage forms with two cores and an opening
US7807197B2 (en) 2002-09-28 2010-10-05 Mcneil-Ppc, Inc. Composite dosage forms having an inlaid portion
EP2255795A1 (en) 2002-09-28 2010-12-01 McNeil-PPC, Inc. Immediate release dosage form comprising shell having openings therein
US20040146559A1 (en) * 2002-09-28 2004-07-29 Sowden Harry S. Dosage forms having an inner core and outer shell with different shapes
US7341742B2 (en) * 2002-09-30 2008-03-11 L. Perrigo Company Simethicone containing tablet composition and method
US20040063664A1 (en) * 2002-09-30 2004-04-01 Danielson Douglas W. Simethicone containing tablet composition and method
US8173161B2 (en) 2002-12-04 2012-05-08 Mcneil-Ppc, Inc. Method of administering a pharmaceutical active ingredient
US20090258039A1 (en) * 2002-12-04 2009-10-15 Bunick Frank J Method of administering a pharmaceutical active ingredient
US20060094787A1 (en) * 2003-03-12 2006-05-04 Patrick Forenzo Pharmaceutical composition comprising 5-methyl-2-2'(chloro-6'-fluoroanilino) phenylacetic acid
US20090048344A1 (en) * 2003-03-12 2009-02-19 Patrick Forenzo Pharmaceutical composition comprising 5-methyl-2-2' (chloro-6'-fluoroanilino phe nylacetic acid
US20040185093A1 (en) * 2003-03-18 2004-09-23 Szymczak Christopher E. Compositions containing sucralose
US20100249237A1 (en) * 2003-03-21 2010-09-30 Gelotte Cathy K Non-Steroidal Anti-Inflammatory Drug Dosing Regimen
US9668993B2 (en) 2003-03-21 2017-06-06 Johnson & Johnson Consumer Inc. Non-steroidal anti-inflammatory drug dosing regimen
US8496969B2 (en) 2003-06-27 2013-07-30 Mcneil-Ppc, Inc. Soft tablet containing high molecular weight cellulosics
US20090104267A1 (en) * 2003-06-27 2009-04-23 David Wynn Soft tablet containing high molecular weight cellulosics
US20100092555A1 (en) * 2003-06-27 2010-04-15 David Wynn Soft tablet containing high molecular weight cellulosics
US20040265373A1 (en) * 2003-06-27 2004-12-30 David Wynn Soft tablet containing high molecular weight cellulosics
US20050069590A1 (en) * 2003-09-30 2005-03-31 Buehler Gail K. Stable suspensions for medicinal dosages
US20050074514A1 (en) * 2003-10-02 2005-04-07 Anderson Oliver B. Zero cycle molding systems, methods and apparatuses for manufacturing dosage forms
US20050095300A1 (en) * 2003-10-30 2005-05-05 Wynn David W. Controlled release analgesic suspensions
US20050095299A1 (en) * 2003-10-30 2005-05-05 Wynn David W. Controlled release analgesic suspensions
US8067029B2 (en) 2004-01-13 2011-11-29 Mcneil-Ppc, Inc. Rapidly disintegrating gelatinous coated tablets
US9149438B2 (en) 2004-01-13 2015-10-06 Johnson & Johnson Consumer Inc. Rapidly disintegrating gelatinous coated tablets
US20050152970A1 (en) * 2004-01-13 2005-07-14 Rinker Roger A. Rapidly disintegrating gelatinous coated tablets
US20110086098A1 (en) * 2004-01-13 2011-04-14 Rinker Roger A Rapidly disintegrating gelatinous coated tablets
US7879354B2 (en) 2004-01-13 2011-02-01 Mcneil-Ppc, Inc. Rapidly disintegrating gelatinous coated tablets
US8815290B2 (en) 2004-01-13 2014-08-26 Mcneil-Ppc, Inc. Rapidly disintegrating gelatinous coated tablets
US20050152971A1 (en) * 2004-01-13 2005-07-14 Rinker Roger A. Rapidly disintegrating gelatinous coated tablets
US20080206337A1 (en) * 2004-03-05 2008-08-28 Hai Yong Huang Method of making dosage forms comprising polymeric compositions
US20050196446A1 (en) * 2004-03-05 2005-09-08 Huang Hai Y. Polymeric compositions and dosage forms comprising the same
US20050196447A1 (en) * 2004-03-05 2005-09-08 Huang Hai Y. Polymeric compositions and dosage forms comprising the same
US20050196442A1 (en) * 2004-03-05 2005-09-08 Huang Hai Y. Polymeric compositions and dosage forms comprising the same
US20050196448A1 (en) * 2004-03-05 2005-09-08 Hai Yong Huang Polymeric compositions and dosage forms comprising the same
EP1602363A1 (en) 2004-06-04 2005-12-07 McNeil-PPC, Inc. Immediate release dosage form comprising shell having openings therein
EP2098224A1 (en) 2004-07-23 2009-09-09 Mcneil-PPC, Inc Rapidly disintegrating gelatinous coated tablets
US20060046998A1 (en) * 2004-08-25 2006-03-02 Fairfield Clinical Trials, Llc Method of treatment of gastroesophageal reflux disease and laryngopharyngeal reflux disease
US20060062811A1 (en) * 2004-09-21 2006-03-23 Szymczak Christopher E Medicinal cooling emulsions
EP2075009A1 (en) 2004-09-21 2009-07-01 McNeil-PPC, Inc. Medicinal cooling emulsions
US20070190133A1 (en) * 2004-10-27 2007-08-16 Bunick Frank J Dosage forms having a microreliefed surface and methods and apparatus for their production
US20060088585A1 (en) * 2004-10-27 2006-04-27 Bunick Frank J Dosage forms having a microreliefed surface and methods and apparatus for their production
US20060088593A1 (en) * 2004-10-27 2006-04-27 Bunick Frank J Dosage forms having a microreliefed surface and methods and apparatus for their production
US20060088586A1 (en) * 2004-10-27 2006-04-27 Bunick Frank J Dosage forms having a microreliefed surface and methods and apparatus for their production
US20060087051A1 (en) * 2004-10-27 2006-04-27 Bunick Frank J Dosage forms having a microreliefed surface and methods and apparatus for their production
US20060088587A1 (en) * 2004-10-27 2006-04-27 Bunick Frank J Dosage forms having a microreliefed surface and methods and apparatus for their production
US20070281022A1 (en) * 2004-10-27 2007-12-06 Bunick Frank J Dosage forms having a microreliefed surface and methods and apparatus for their production
US8383159B2 (en) 2004-10-27 2013-02-26 Mcneil-Ppc, Inc. Dosage forms having a microreliefed surface and methods and apparatus for their production
US8673352B2 (en) 2005-04-15 2014-03-18 Mcneil-Ppc, Inc. Modified release dosage form
US8007825B2 (en) 2005-09-30 2011-08-30 Mcneil-Ppc, Inc. Oral compositions containing a salivation inducing agent
US20090191267A1 (en) * 2005-09-30 2009-07-30 Wynn David W Oral Compositions Containing a Salivation Inducing Agent
US20080103206A1 (en) * 2006-10-20 2008-05-01 Jim Swann Acetaminophen / ibuprofen combinations and method for their use
EP3292866A1 (en) 2006-10-20 2018-03-14 Johnson & Johnson Consumer Inc. Acetaminophen / ibuprofen combinations
US8580856B2 (en) 2006-10-20 2013-11-12 Ncneil-Ppc, Inc. Acetaminophen/ibuprofen combinations and method for their use
US8580855B2 (en) 2006-10-20 2013-11-12 Mcneil-Ppc, Inc. Acetaminophen / ibuprofen combinations and method for their use
US20080113021A1 (en) * 2006-10-25 2008-05-15 Robert Shen Ibuprofen composition
US8771716B2 (en) 2006-11-21 2014-07-08 Mcneil-Ppc, Inc. Modified release analgesic suspensions
US8394415B2 (en) 2006-11-21 2013-03-12 Mcneil-Ppc, Inc Modified release analgesic suspensions
US20080311201A1 (en) * 2007-06-12 2008-12-18 Lee Der-Yang Modified release solid or semi-solid dosage forms
US9833510B2 (en) 2007-06-12 2017-12-05 Johnson & Johnson Consumer Inc. Modified release solid or semi-solid dosage forms
US20090004248A1 (en) * 2007-06-29 2009-01-01 Frank Bunick Dual portion dosage lozenge form
US20090060983A1 (en) * 2007-08-30 2009-03-05 Bunick Frank J Method And Composition For Making An Orally Disintegrating Dosage Form
US20100021507A1 (en) * 2007-08-30 2010-01-28 Bunick Frank J Method and Composition for Making an Orally Disintegrating Dosage Form
US20090074866A1 (en) * 2007-09-17 2009-03-19 Jen-Chi Chen Dip coated compositions containing copolymer of polyvinyl alcohol and polyethylene glycol and a gum
US20090110716A1 (en) * 2007-10-31 2009-04-30 Frank Bunick Orally disintegrative dosage form
US20100016348A1 (en) * 2007-10-31 2010-01-21 Frank Bunick Orally disintegrative dosage form
US20100016451A1 (en) * 2007-10-31 2010-01-21 Frank Bunick Orally Disintegrative Dosage Form
US8968769B2 (en) 2007-10-31 2015-03-03 Mcneil-Ppc, Inc. Orally disintegrative dosage form
US20090162435A1 (en) * 2007-12-21 2009-06-25 Bunick Frank J Manufacture of tablet
US8357395B2 (en) 2007-12-21 2013-01-22 Mcneil-Ppc, Inc. Manufacture of tablet
US20090196908A1 (en) * 2008-01-31 2009-08-06 Der-Yang Lee Edible film-strips with modified release active ingredients
US20090196907A1 (en) * 2008-01-31 2009-08-06 Bunick Frank J Edible film-strips for immediate release of active ingredients
US8722089B2 (en) 2008-02-19 2014-05-13 Mcneil-Ppc, Inc. Dip coated compositions containing a starch having a high amylose content
US20090208574A1 (en) * 2008-02-19 2009-08-20 Jen-Chi Chen Dip coated compositions containing a starch having a high amylose content
US20090324716A1 (en) * 2008-06-26 2009-12-31 Robert Shen Coated Particles Containing Pharmaceutically Active Agents
US8282957B2 (en) 2008-06-26 2012-10-09 Mcneil-Ppc, Inc. Coated particles containing pharmaceutically active agents
WO2010006029A2 (en) 2008-07-08 2010-01-14 Hyperbranch Medical Technology, Inc. Self-contained medical applicators for multiple component formulations, and methods of use thereof
US20100112052A1 (en) * 2008-10-31 2010-05-06 Vincent Chen Osmotic tablet with a compressed outer coating
US20100247586A1 (en) * 2009-03-27 2010-09-30 Andreas Hugerth Multi-Portion Intra-Oral Dosage Form With Organoleptic Properties
US20100330169A1 (en) * 2009-06-29 2010-12-30 Frank Bunick Pharmaceutical Tablet Containing A Liquid Filled Capsule
WO2011002702A1 (en) 2009-06-29 2011-01-06 Mcneil-Ppc, Inc. Pharmaceutical tablet containing a liquid filled capsule
WO2011038094A1 (en) 2009-09-24 2011-03-31 Mcnell-Ppc, Inc. Manufacture of lozenge product with radiofrequency
WO2011038101A1 (en) 2009-09-24 2011-03-31 Mcneil-Ppc, Inc. Manufacture of chewing gum product with radiofrequency
US20110071183A1 (en) * 2009-09-24 2011-03-24 Jen-Chi Chen Manufacture of lozenge product with radiofrequency
US9107807B2 (en) 2009-09-24 2015-08-18 Mcneil-Ppc, Inc. Machine for the manufacture of dosage forms utilizing radiofrequency energy
US8807979B2 (en) 2009-09-24 2014-08-19 Mcneil-Ppc, Inc. Machine for the manufacture of dosage forms utilizing radiofrequency energy
WO2011038064A2 (en) 2009-09-24 2011-03-31 Mcneil-Ppc, Inc. Manufacture of tablet in a die utilizing powder blend containing water-containing material
WO2011038077A1 (en) 2009-09-24 2011-03-31 Mcneil-Ppc, Inc. Machine for the manufacture of dosage forms utilizing radiofrequency energy
US8871263B2 (en) 2009-09-24 2014-10-28 Mcneil-Ppc, Inc. Manufacture of tablet in a die utilizing radiofrequency energy and meltable binder
US8858210B2 (en) 2009-09-24 2014-10-14 Mcneil-Ppc, Inc. Manufacture of variable density dosage forms utilizing radiofrequency energy
US20110071185A1 (en) * 2009-09-24 2011-03-24 Bunick Frank J Manufacture of tablet in a die utilizing powder blend containing water-containing material
US20110071184A1 (en) * 2009-09-24 2011-03-24 Bunick Frank J Manufacture of tablet in a die utilizing radiofrequency energy and meltable binder
US8343533B2 (en) 2009-09-24 2013-01-01 Mcneil-Ppc, Inc. Manufacture of lozenge product with radiofrequency
US20110070286A1 (en) * 2009-09-24 2011-03-24 Andreas Hugerth Process for the manufacture of nicotine-comprising chewing gum and nicotine-comprising chewing gum manufactured according to said process
US9610224B2 (en) 2009-09-24 2017-04-04 Johnson & Johnson Consumer Inc. Manufacture of tablet in a die utilizing powder blend containing water-containing material
US8313768B2 (en) 2009-09-24 2012-11-20 Mcneil-Ppc, Inc. Manufacture of tablet having immediate release region and sustained release region
WO2011049706A1 (en) 2009-09-24 2011-04-28 Mcneil-Ppc, Inc. Orally transformable tablets
US8784781B2 (en) 2009-09-24 2014-07-22 Mcneil-Ppc, Inc. Manufacture of chewing gum product with radiofrequency
US8865204B2 (en) 2009-09-24 2014-10-21 Mcneil-Ppc, Inc. Manufacture of lozenge product with radiofrequency
US8329221B2 (en) 2009-11-05 2012-12-11 Fmc Corporation Microcrystalline cellulose and calcium phosphate compositions useful as pharmaceutical excipients
US20110104288A1 (en) * 2009-11-05 2011-05-05 Fmc Corporation Microcrystalline Cellulose and Calcium Phosphate Compositions Useful as Pharmaceutical Excipients
WO2011056775A3 (en) * 2009-11-05 2011-11-03 Fmc Corporation Microcrystalline cellulose and calcium phosphate compositions useful as pharmaceutical excipients
WO2012039790A1 (en) 2010-09-22 2012-03-29 Mcneil-Ppc, Inc. Manufacture of tablets from energy-applied powder blend
WO2012039788A1 (en) 2010-09-22 2012-03-29 Mcneil-Ppc, Inc. Multi-layered orally disintegrating tablet and the manufacture thereof
WO2012039789A1 (en) 2010-09-22 2012-03-29 Mcneil-Ppc, Inc. Manufacture of variable density dosage forms utilizing radiofrequency energy
US20150119422A1 (en) * 2011-12-14 2015-04-30 Disphar International B.V. Simethicone formulation
WO2013095111A1 (en) 2011-12-14 2013-06-27 Disphar International B.V. Simethicone formulation
US8900632B2 (en) 2012-02-07 2014-12-02 Mcneil-Ppc, Inc. Rapidly disintegrating coated tablets
WO2013119466A1 (en) 2012-02-07 2013-08-15 Mcneil-Ppc, Inc. Rapidly disintegrating coated tablets
US9511028B2 (en) 2012-05-01 2016-12-06 Johnson & Johnson Consumer Inc. Orally disintegrating tablet
WO2013166131A2 (en) 2012-05-01 2013-11-07 Mcneil-Ppc, Inc. Orally disintegrating tablet
US9445971B2 (en) 2012-05-01 2016-09-20 Johnson & Johnson Consumer Inc. Method of manufacturing solid dosage form
WO2013166144A1 (en) 2012-05-01 2013-11-07 Mcneil-Ppc, Inc. Method of manufacturing solid dosage form
US9233491B2 (en) 2012-05-01 2016-01-12 Johnson & Johnson Consumer Inc. Machine for production of solid dosage forms
WO2013166136A1 (en) 2012-05-01 2013-11-07 Mcneil-Ppc, Inc. Tablet comprising a first and second region
WO2013166138A1 (en) 2012-05-01 2013-11-07 Mcneil-Ppc, Inc. Machine for production of solid dosage forms
US9789066B2 (en) 2014-01-10 2017-10-17 Johnson & Johnson Consumer Inc. Process for making tablet using radiofrequency and lossy coated particles
WO2015105992A1 (en) 2014-01-10 2015-07-16 Mcneil-Ppc, Inc. Process for making tablet using radiofrequency and lossy coated particles
WO2018017553A2 (en) 2016-07-19 2018-01-25 Johnson & Johnson Consumer Inc. Tablets having discontinuous coated regions

Also Published As

Publication number Publication date Type
EP0891776A1 (en) 1999-01-20 application
DE69821553T2 (en) 2004-12-23 grant
CN1207898A (en) 1999-02-17 application
DE69821553D1 (en) 2004-03-18 grant
ES2216244T3 (en) 2004-10-16 grant
CN1267106C (en) 2006-08-02 grant
EP0891776B1 (en) 2004-02-11 grant
DK891776T3 (en) grant
JPH1192387A (en) 1999-04-06 application
RU2216317C2 (en) 2003-11-20 grant
DK0891776T3 (en) 2004-05-10 grant

Similar Documents

Publication Publication Date Title
Kanig Properties of fused mannitol in compressed tablets
US5273758A (en) Directly compressible polyethylene oxide vehicle for preparing therapeutic dosage forms
US6589554B1 (en) Tablets quickly disintegrating in the oral cavity and process for producing the same
US6287596B1 (en) Quickly disintegratable compression-molded materials and process for producing the same
US5462747A (en) Pharmaceutical sustained release matrix
US5494681A (en) Tastemasked pharmaceutical materials
US6432442B1 (en) Chewable product
US5733577A (en) Delivery of controlled-release system (s)
US6589556B2 (en) Rapid-melt semi-solid compositions, methods of making same and methods of using same
US6602518B2 (en) Chewable product including active ingredient
US5965162A (en) Process for forming chewable quickly dispersing multi-vitamin preparation and product therefrom
US5169640A (en) Pharmaceutical compositions
US5753254A (en) Therapeutic agents containing thyroid hormones
US3950508A (en) Process for obtaining pharmaceutical sustained releases
US5211958A (en) Pharmaceutical composition and process for its preparation
US4396604A (en) Simethicone antacid lozenge
US5102665A (en) Pharmaceutical compositions
US20030124184A1 (en) Quick disolve compositions and tablets based thereon
US6475510B1 (en) Process for manufacturing bite-dispersion tablets
US7179486B1 (en) Process for preparing sustained release tablets
US6358526B1 (en) Method of making tablets and tablet compositions produced therefrom
US5989588A (en) Methods and compositions for preventing and treating heartburn
US20070196472A1 (en) Phenylephrine tannate and pyrilamine tannate salts in pharmaceutical compositions
US20050019398A1 (en) Flashmelt oral dosage formulation
US5069910A (en) Dispersible cimetidine tablets

Legal Events

Date Code Title Description
AS Assignment

Owner name: MCNEIL PPC-INC, NEW JERSEY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LUBER, JOSEPH R.;MADISON, GLENN;MCNALLY, GERARD;REEL/FRAME:008931/0869

Effective date: 19980122

FPAY Fee payment

Year of fee payment: 4

FPAY Fee payment

Year of fee payment: 8

FPAY Fee payment

Year of fee payment: 12